Skip to main content
HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Staff banner

Staff Profile: Michael G. Kurilla

Michael G. Kurilla, M.D., Ph.D.
Michael G. Kurilla, M.D., Ph.D.

Director

Division of Clinical Innovation

National Center for Advancing Translational Sciences

National Institutes of Health

Email Michael G. Kurilla

Biography

Michael Kurilla is the director of the Division of Clinical Innovation at NCATS. In this capacity, he oversees the Clinical and Translational Science Awards (CTSA) Program, which supports innovative solutions to advance the efficiency, quality and impact of translational science, with the ultimate goal of getting more treatments to more patients more quickly. Prior to joining NCATS, Kurilla served as the director of the Office of Biodefense Research Resources and Translational Research within the National Institute of Allergy and Infectious Diseases (NIAID), where he focused on translational efforts toward infectious disease product development, including vaccines, therapeutics and diagnostics, with emphasis on biodefense and emerging infectious disease threats. Prior to joining NIAID in 2003, Kurilla was an associate director for infectious diseases at Wyeth. He also worked in antimicrobials at DuPont and on clinical microbiology and molecular pathology at the University of Virginia Health Sciences Center.

Kurilla received his M.D. and his Ph.D. in microbiology and immunology from Duke University. He was a postdoctoral research fellow at Harvard Medical School and completed a residency in pathology at Brigham and Women’s Hospital. He received a B.S. in chemistry from the California Institute of Technology.

Research Topics

Kurilla’s research interests include all facets of translational science, especially innovative and novel interventional concepts requiring additional input from regulatory science to enable viable, robust developmental pathways.

Selected Publications

  1. Accelerating global innovation to address antibacterial resistance: introducing CARB-X.
  2. High priority preparedness research and its support.
  3. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.